Dear Grevel,
could you kindly point out the reference where this statment comes from: "A further trick to make it all work is to logarithmically transform all concentrations as recommended by Mats Karlsson." thanks ________________________________ From: "Grevel, Joachim" <joachim.gre...@astrazeneca.com> To: nmusers@globomaxnm.com Sent: Tuesday, August 4, 2009 3:21:57 AM Subject: RE: [NMusers] OMEGA-Block Dear Hauke, thanks for including portions of your control stream and output. Leonid explained to you the rationale of preferring V1 and V2 over V1 and VSS. I personally (not a company policy) routinely would use all four etas the way you did, but with a full set of covariates. I would also take out some of the correlation by allometricallly (by a size covariate) scaling all volumes and clearances according to the Holford paradigm (see NMusers on 3/4 rule). A further trick to make it all work is to logarithmically transform all concentrations as recommended by Mats Karlsson. I go through all this trouble in order to capture "all" between patient variability and to prevent it from spilling over into unexplained (residual) variability. I am not bothered too much by warnings and refused covariance steps. I verify my pivotal models with bootstraps. When it comes to simulations with your final (validated) model you will reap the fruits of your labor. Hope that is of some use to you, Joachim _________________________________ AstraZeneca R&D Charnwood Clin. Pharmacology and DMPK Bakewell Road Loughborough, LE11 5RH Tel: +44 1509 644035 joachim.gre...@astrazeneca.com -------------------------------------------------------------------------- AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 15 Stanhope Gate, London W1K 1LN. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking Compliance with our Code of Conduct and Policies. -----Original Message----- From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com]on Behalf Of Hauke Rühs Sent: 03 August 2009 17:06 To: nmusers@globomaxnm.com Subject: Re: [NMusers] OMEGA-Block Dear NMusers, thank you for your responses. I parameterized the model by VSS, because the estimation of the parameter became much better, in terms of varability, compared to parameterization by V1 and V2. This is the excerpt from my control stream and output file: $PK CL = THETA(1) * EXP(ETA(1)) Q = THETA(2) * EXP(ETA(2)) V1 = THETA(3)* EXP(ETA(3)) VSS = THETA(4) * EXP(ETA(4)) V2=VSS-V1 $OMEGA 0.1 ; OMCL 0.5 ;OMQ $OMEGA BLOCK(2) 0.05 ;OMV1 0.01 0.05 ;OMVSS OMEGA - COV MATRIX FOR RANDOM EFFECTS - ETAS ******** ETA1 ETA2 ETA3 ETA4 ETA1 + 4.08E-02 ETA2 + 0.00E+00 4.56E-01 ETA3 + 0.00E+00 0.00E+00 2.62E-01 ETA4 + 0.00E+00 0.00E+00 -4.34E-02 7.20E-03 Best regards Hauke Am 03.08.2009, 16:37 Uhr, schrieb Grevel, Joachim <joachim.gre...@astrazeneca.com>: > Hello Hauke, > > as always for these specific questions you need to provide us with the > relevant portions of your control stream and of your output. > > Thanks for participating, > > Joachim > _________________________________ > AstraZeneca R&D Charnwood > Clin. Pharmacology and DMPK > Bakewell Road > Loughborough, LE11 5RH > Tel: +44 1509 644035 > joachim.gre...@astrazeneca.com > > > > -------------------------------------------------------------------------- > AstraZeneca UK Limited is a company incorporated in England and Wales > with registered number: 03674842 and a registered office at 15 Stanhope > Gate, London W1K 1LN. > Confidentiality Notice: This message is private and may contain > confidential, proprietary and legally privileged information. If you > have received this message in error, please notify us and remove it from > your system and note that you must not copy, distribute or take any > action in reliance on it. Any unauthorised use or disclosure of the > contents of this message is not permitted and may be unlawful. > Disclaimer: Email messages may be subject to delays, interception, > non-delivery and unauthorised alterations. Therefore, information > expressed in this message is not given or endorsed by AstraZeneca UK > Limited unless otherwise notified by an authorised representative > independent of this message. No contractual relationship is created by > this message by any person unless specifically indicated by agreement in > writing other than email. > Monitoring: AstraZeneca UK Limited may monitor email traffic data and > content for the purposes of the prevention and detection of crime, > ensuring the security of our computer systems and checking Compliance > with our Code of Conduct and Policies. > -----Original Message----- > From: owner-nmus...@globomaxnm.com > [mailto:owner-nmus...@globomaxnm.com]on Behalf Of Hauke Rühs > Sent: 03 August 2009 15:07 > To: nmusers@globomaxnm.com > Subject: [NMusers] OMEGA-Block > > > > Dear NMusers, > > modelling a 2-compartmet model parameterized by CL, V1, VSS and Q, I got > to a problem with which I don’t know how to deal with: After choosing my > structural and statistic model (combined residual error model) I > estimated > the covariance matrix by including an OMEGA-BLOCK(4), which reduced the > OFV by 15. The correlations between the parameters were all estimated to > be minor (< 0.8). But when I model with a BLOCK(2) on VSS and V1, which I > would expect to be positively correlated, the correlation is estimated to > be -0.99. Additionally, the inclusion of BLOCK(2) does not significantly > improve the OFV. > So does it, after all, still make sense to include the BLOCK(2)? > Generally, at which step of model-building would you recommend to test > for > parameter correlation? > > Thanking you in advance, > > Hauke > > ----------------------------- > Hauke Rühs > > Apotheker > Pharmazeutisches Institut > - Klinische Pharmazie - > An der Immenburg 4 > > 53121 Bonn > > Tel: + 49-(0)228 73-5781 > Fax: + 49-(0)228 73-9757 > > www.klinische-pharmazie.info > >
